as a member of its Supervisory Board.
Serial entrepreneur in biotech, Mr. Lafay’s decades of experience, his vision and network will bolster Axoltis’ strategic corporate development
Clermont-Ferrand and Lyon, France, July 9, 2024 – Axoltis Pharma, a French biopharmaceutical company focused on developing therapeutic solutions for neurodegenerative diseases, today announces the appointment of Jean-Guillaume Lafay as a member of its Supervisory Board.
“Axoltis is delighted to welcome Jean-Guillaume Lafay to our Supervisory Board. His stellar track record in biotech and success as an entrepreneur will greatly strengthen our ambition and our vision,” said Dr. Yann Godfrin, CEO of Axoltis. “Combining his talent with our experience will also reinforce our strategic direction and ability to achieve key milestones.”